[1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | STEWART, LORNA PAVE, GREGOIRE, ALEXANDRE WYNNE, EMMA, LOUISE RIGOREAU, LAURENT, JEAN, MARTIN FIRTH, JAMES, DONALD |
| description | The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2217578B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2217578B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2217578B13</originalsourceid><addsrcrecordid>eNrjZIiONtQx0jGJDQnydIzy9_EHck11HWMDIoM8XTz9XBUc_VwUsClxBivxhShy9vcN8A_1cwkGKw_xcPUMUggNduVhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAUZGhuam5hZOhsZEKAEA_ksxeQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>[1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE</title><source>esp@cenet</source><creator>STEWART, LORNA ; PAVE, GREGOIRE, ALEXANDRE ; WYNNE, EMMA, LOUISE ; RIGOREAU, LAURENT, JEAN, MARTIN ; FIRTH, JAMES, DONALD</creator><creatorcontrib>STEWART, LORNA ; PAVE, GREGOIRE, ALEXANDRE ; WYNNE, EMMA, LOUISE ; RIGOREAU, LAURENT, JEAN, MARTIN ; FIRTH, JAMES, DONALD</creatorcontrib><description>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131204&DB=EPODOC&CC=EP&NR=2217578B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20131204&DB=EPODOC&CC=EP&NR=2217578B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>STEWART, LORNA</creatorcontrib><creatorcontrib>PAVE, GREGOIRE, ALEXANDRE</creatorcontrib><creatorcontrib>WYNNE, EMMA, LOUISE</creatorcontrib><creatorcontrib>RIGOREAU, LAURENT, JEAN, MARTIN</creatorcontrib><creatorcontrib>FIRTH, JAMES, DONALD</creatorcontrib><title>[1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE</title><description>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIiONtQx0jGJDQnydIzy9_EHck11HWMDIoM8XTz9XBUc_VwUsClxBivxhShy9vcN8A_1cwkGKw_xcPUMUggNduVhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAUZGhuam5hZOhsZEKAEA_ksxeQ</recordid><startdate>20131204</startdate><enddate>20131204</enddate><creator>STEWART, LORNA</creator><creator>PAVE, GREGOIRE, ALEXANDRE</creator><creator>WYNNE, EMMA, LOUISE</creator><creator>RIGOREAU, LAURENT, JEAN, MARTIN</creator><creator>FIRTH, JAMES, DONALD</creator><scope>EVB</scope></search><sort><creationdate>20131204</creationdate><title>[1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE</title><author>STEWART, LORNA ; PAVE, GREGOIRE, ALEXANDRE ; WYNNE, EMMA, LOUISE ; RIGOREAU, LAURENT, JEAN, MARTIN ; FIRTH, JAMES, DONALD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2217578B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2013</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>STEWART, LORNA</creatorcontrib><creatorcontrib>PAVE, GREGOIRE, ALEXANDRE</creatorcontrib><creatorcontrib>WYNNE, EMMA, LOUISE</creatorcontrib><creatorcontrib>RIGOREAU, LAURENT, JEAN, MARTIN</creatorcontrib><creatorcontrib>FIRTH, JAMES, DONALD</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>STEWART, LORNA</au><au>PAVE, GREGOIRE, ALEXANDRE</au><au>WYNNE, EMMA, LOUISE</au><au>RIGOREAU, LAURENT, JEAN, MARTIN</au><au>FIRTH, JAMES, DONALD</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>[1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE</title><date>2013-12-04</date><risdate>2013</risdate><abstract>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP2217578B1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| title | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T10%3A57%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=STEWART,%20LORNA&rft.date=2013-12-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2217578B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |